Skip to content
Screener

Immunome IMNM Free cash flow margin

Free cash flow margin at other companies

Pfizer logo
PfizerPFE
18%+8.8pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-406%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-212%-95.8pp
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-450.7%-524pp
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-366.6%+1,421pp
Gilead Sciences logo
Gilead SciencesGILD
42.5%+10.0pp

Other financials

Income statement

See full
Revenue--100%
Operating income-$59.3M-32.9%
Net income-$53.8M-29.3%
EPS (diluted)-$0.48+7.7%

Balance sheet

See full
Cash & equivalents$582.7M+126%
Total debt$3.7M-22.6%
Total equity$588.7M+91.7%
Total assets$619.8M+80.9%

Cash flow

See full
Operating cash flow-$58.6M-10.5%
CapEx$3.0M-18.1%
Free cash flow-$61.6M-8.7%

Valuation

See full
Market cap$2.92B+221%
Enterprise value$2.35B+204%
P/S728.3×+656×

Profitability

See full
Operating margin-5,947.9%-12,002pp
Net margin-5,593.8%-11,284pp

Returns & leverage

See full
Return on equity-50.1%-10.8pp
Debt / equity0.0×
Current ratio21.7×+11.2×

Where this comes from

Calculated from Immunome’s reported figures.

Based on trailing twelve months.

The source filing: Immunome’s 10-Q, filed May 12, 2026. Open the filing →

Filed
May 12, 2026, 4:10 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219425

FAQ

What is Immunome's free cash flow margin?
Immunome (IMNM) reported free cash flow margin of -5,118.9% in Q1 2026.
How has Immunome's free cash flow margin changed year-over-year?
Immunome's free cash flow margin decreased by 247.0% year-over-year, from -1,475.2% to -5,118.9%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.

Ask your AI about Immunome's free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude